Table 1

Characteristics and design of the studies

Study	Number of patients with HFpEF	Age (years)	Women	LVEF criteria	LV strain (GLS)	Control group	Follow-up
Wang et al4	20	63 ± 16	35%	≥ 50%	18 LV segments - EchoPac	yes	no
Liu et al5	26	68 ± 13	31%	≥ 50%	18 LV segments - EchoPac	yes	no
Phan et al27	40	67 ± 10	73%	> 50%	12 LV segments - EchoPac	yes	no
Tan et al6	56	72 ± 7	69.6%	> 50%	12 LV segments - EchoPac	yes	no
Kasner et al28	21	51 ± 4.2	52%	≥ 50%	18 LV segments - EchoPac	yes	no
Morris et al7	119	70 ± 10	44%	> 50%	18 LV segments - EchoPac	yes	no
Yip et al8	112	74 ± 12	64%	≥ 50%	18 LV segments - EchoPac	yes	no
Abe et al9	10	65 ± 12	30%	≥ 50%	16 LV segments - TomTec	yes	not reported in HFpEF
Obokata et al10	40	77 ± 13	65%	> 50%	18 LV segments - EchoPac	yes	no
Pellicori et al29	138	78 ± 10	37%	≥ 50%	18 LV segments - EchoPac	yes	28 months
Kraigher-Krainer et al11	219	71 ± 9	61%	≥ 45%	12 LV segments - TomTec	yes	no
Menet et al12	40	70 ± 13	77%	≥ 50%	18 LV segments - EchoPac	yes	no
Luo et al13	58	70 ± 10	40%	≥ 50%	16 LV segments - Toshiba	yes	no
Donal et al19 20	356	76 ± 9	55.9%	> 45%	18 LV segments - EchoPac	no	28 months
Wang et al30	80	66 ± 8	37%	> 50%	18 LV segments - EchoPac	no	36 months
Stampehl et al14	100	60 ± 1	76%	≥ 50%	18 LV segments - EchoPac	no	12 months
Shah et al15	447	70.3 ± 9.8	53.7%	≥ 45%	12 LV segments - TomTec	yes	31 months
Kosmala et al16	207	63.7 ± 8.6	73%	≥ 50%	18 LV segments - EchoPac	yes	no
Morris et al17	218	72 ± 10.5	52.3%	> 50%	18 LV segments - EchoPac	yes	no
Toufan et al18	126	57.5 ± 10	69.8%	≥ 50%	16 LV segments - EchoPac	yes	no
Freed et al31	308	65 ± 13	64%	≥ 50%	12 LV segments - TomTec	no	13 months
Carluccio et al21	46	75 ± 8	52%	≥ 50%	18 LV segments - EchoPac	yes	no
Iwano et al22	50	59 ± 16	70%	≥ 50%	12 LV segments - QLab	yes	no
Hung et al23	58	64.3 ± 12.4	53.4%	> 50%	18 LV segments - EchoPac	yes	no
Obokata et al32	102	77 ± 11	57%	≥ 45%	18 LV segments - Epsilon	no	12 months
DeVore et al33	187	69 ± 2.5	48.1%	≥ 50%	18 LV segments - TomTec	no	6 months
Huang et al24	129	75.1 ± 10.7	58%	≥ 45%	18 LV segments - EchoPac	no	36 months
Lo et al25	74	73.8 ± 17	60.8%	≥ 50%	18 LV segments - EchoPac	yes	no
Bosch et al26	159	68 ± 11	52%	≥ 50%	18 LV segments - EchoPac	yes	24 months

In the study by Bosch et al,26 159 out of 219 patients were feasible to perform GLS analyses and the reported follow-up with outcomes analysis did not include GLS. The studies by Donal et al19 20 included a first outcomes analysis on GLS using a continuous Cox regression analysis and a second post hoc outcomes analysis on GLS using a dichotomous Cox regression analysis.
GLS, global longitudinal systolic strain; HFpEF, heart failure with preserved ejection fraction; LV, left ventricular; LVEF, left ventricular ejection fraction.